Updated: January 25, 2026
What Is Vascepa? Uses, Dosage, and What You Need to Know in 2026
Author
Peter Daggett

Overview
A complete 2026 overview of Vascepa (icosapent ethyl) — what it is, what it treats, how to take it, and what patients need to know before starting this cardiovascular medication.
Is Vascepa in stock near you?
Medfinder checks real pharmacy inventory — start a search and we'll find Vascepa near you.
If your doctor recently prescribed Vascepa, you're likely wondering exactly what it is, how it works, and whether it's truly different from the fish oil supplements you've seen at the pharmacy. The answer is yes — significantly different. Here's everything you need to know about Vascepa (icosapent ethyl) in 2026.
What Is Vascepa?
Vascepa is a brand-name prescription medication manufactured by Amarin Pharma, Inc. Its active ingredient is icosapent ethyl (IPE) — a highly purified ethyl ester form of eicosapentaenoic acid (EPA), an omega-3 fatty acid. Unlike over-the-counter fish oil supplements, which contain a blend of omega-3 fatty acids including both EPA and DHA (docosahexaenoic acid), Vascepa contains only one active ingredient: highly purified EPA.
Vascepa was first approved by the FDA in 2012 for reducing triglycerides in adults with very high levels, and then in December 2019 it became the first medication specifically approved to reduce cardiovascular risk in patients with elevated triglycerides who are already on statin therapy. The drug has been prescribed more than 25 million times globally.
Check live stock now.
What Is Vascepa Approved to Treat?
The FDA has approved Vascepa for two indications:
- Cardiovascular risk reduction: As an adjunct to maximally tolerated statin therapy, to reduce the risk of myocardial infarction (heart attack), stroke, coronary revascularization, and unstable angina requiring hospitalization. Patients must have triglycerides ≥150 mg/dL and either established cardiovascular disease or Type 2 diabetes with at least 2 additional CV risk factors.
- Severe hypertriglyceridemia: As an adjunct to diet to reduce triglyceride levels in adults with triglycerides ≥500 mg/dL. This is a standalone indication and does not require statin use or existing cardiovascular disease.
The cardiovascular risk reduction indication is unique to Vascepa among prescription omega-3 products — it's based on the landmark REDUCE-IT clinical trial, which enrolled 8,179 patients and showed Vascepa reduced the risk of major cardiovascular events by 25% compared to placebo.
Vascepa vs. Fish Oil: What's the Difference?
This is one of the most common questions patients ask. Vascepa is not fish oil. Here's the key distinction:
- Vascepa is a single, highly purified form of EPA. It undergoes rigorous FDA manufacturing standards. It has proven cardiovascular outcomes data from a large randomized clinical trial.
- OTC fish oil supplements contain a mix of EPA and DHA (and sometimes other compounds), vary in purity and potency between brands, are not FDA-approved medications, and have NOT been shown in large clinical trials to reduce cardiovascular events.
This is not just a matter of concentration. The clinical evidence base for Vascepa's cardiovascular benefits does not extend to OTC fish oil products. Do not substitute one for the other without talking to your doctor.
Vascepa Dosage: How Much Do You Take?
The approved dosage for both of Vascepa's indications is the same:
- Total daily dose: 4 grams per day
- Divided into: 2 grams twice daily (morning and evening)
- Capsule options: 2 grams can be taken as two 1g capsules or four 0.5g capsules per dose
- With food: Always take with or immediately after a meal
- Swallow whole: Do not break, crush, dissolve, or chew the capsules
If you miss a dose, take it as soon as you remember — but if you miss an entire day, do not double up the next day.
Who Should NOT Take Vascepa?
Vascepa is contraindicated in patients with:
- Known hypersensitivity (including anaphylaxis) to icosapent ethyl or any ingredient in Vascepa
Use with extra caution and discuss with your doctor if you have:
- A fish or shellfish allergy — the potential for allergic reaction exists, though risk is not fully established
- A history of atrial fibrillation or atrial flutter
- Current use of blood thinners or antiplatelet medications (aspirin, warfarin, clopidogrel)
- Liver problems (liver function should be monitored)
Is a Generic Available?
Yes. Generic icosapent ethyl has been available since 2020 from multiple FDA-approved manufacturers. It is bioequivalent to brand-name Vascepa and is typically available at a lower cost. Ask your doctor or pharmacist about the generic option.
Found
Rate
on average
Where to Fill Your Vascepa Prescription
Not all pharmacies reliably stock Vascepa. If you're having trouble finding it, medfinder.com can help by contacting pharmacies in your area to locate which ones have it in stock. For information on reducing your cost, see our guide to how to save money on Vascepa in 2026.
Frequently Asked Questions
Vascepa (icosapent ethyl) is FDA-approved for two uses: (1) reducing the risk of heart attack, stroke, and certain hospitalization-requiring cardiac events in adults with triglycerides ≥150 mg/dL who have established cardiovascular disease or diabetes with additional risk factors and are on statin therapy; and (2) reducing triglyceride levels in adults with severe hypertriglyceridemia (TG ≥500 mg/dL) as an adjunct to diet.
Vascepa is not a fish oil supplement. It contains a single, highly purified form of EPA (icosapent ethyl) manufactured under FDA pharmaceutical standards. Over-the-counter fish oil supplements contain a mix of omega-3 fatty acids, vary in purity, and are not FDA-regulated as drugs. Most importantly, the cardiovascular risk-reduction benefits proven for Vascepa in the REDUCE-IT trial have not been demonstrated for OTC fish oil.
The recommended dose is 4 grams per day, taken as 2 grams twice daily (morning and evening) with food. Each 2-gram dose can be taken as two 1g capsules or four 0.5g capsules. Capsules must be swallowed whole — do not crush or chew them. Do not double up if you miss a day.
The FDA approved Vascepa's cardiovascular risk reduction indication in December 2019, based on results from the REDUCE-IT clinical trial. This made Vascepa the first drug specifically approved to reduce cardiovascular risk in patients with elevated triglyceride levels. Vascepa was originally approved in 2012 for treating severe hypertriglyceridemia.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Vascepa also looked for:
More about Vascepa
39,049 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.





